Erlotinib for preventing liver cancer
Part of Cancer, Digestive system clinical trials.
This trial tests whether the drug erlotinib can help prevent liver cancer in people with advanced liver scarring or cirrhosis. It might help by stopping liver cells from becoming cancerous.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older
- You must have advanced liver fibrosis or cirrhosis
- You must not have liver decompensation, which means your liver is not currently failing
- You must never have had liver cancer
- Your liver fibrosis score (FIB-4) must be greater than 3.25
- Your liver function test (PLSec) score must be 3 or higher
- You must be in generally good health, with a performance status score of at least 70
- You must not have taken EGFR inhibitor drugs before
- You must not be taking certain medications that could interact with erlotinib
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a green tea extract called EGCG can prevent liver cancer in people with cirrhosis. It looks at how the extract affects liver cell changes that could lead to cancer.
This trial tests a combination of two or three drugs for advanced liver cancer that cannot be removed with surgery. The goal is to see if adding a third drug (gefitinib) to the standard two-drug combination helps patients live longer with better quality of life.
This trial tests the drug lenvatinib (a pill that helps stop cancer growth) as a first treatment for people with liver cancer that cannot be surgically removed and who have moderate liver damage. It aims to see if lenvatinib can help control the cancer and improve outcomes.
This trial tests new treatment plans for people with advanced liver cancer that has worsened after initial therapy. The goal is to find more effective, personalized options based on how your cancer responds.
This trial tests whether atorvastatin (a cholesterol medicine) can lower the chance of liver cancer (HCC) in people with advanced liver scarring or cirrhosis. Participants are compared to placebo (inactive pill) while researchers track safety and cancer risk.
This trial tests a combination of two drugs (lenvatinib and toripalimab, a type of immunotherapy) plus a special chemotherapy infusion directly into the liver artery for people with advanced liver cancer that has not been treated before. The goal is to see if adding the immunotherapy helps shrink tumors better than the standard combination.
Hear when a new Cirrhosis, Liver trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.